Tomi K. Sawyer

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

Thomas O’Hare, William C. Shakespeare, Xiaotian Zhu et al. · Cancer Cell · 2009 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +9

Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy

Yong S. Chang, Bradford Graves, Vincent Guerlavais et al. · Proceedings of the National Academy of Sciences · 2013 · 661 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +15

4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity.

Tomi K. Sawyer, Pauline J. Sanfilippo, Victor J. Hruby et al. · Proceedings of the National Academy of Sciences · 1980 · 578 citations · Full text

Life Sciences, Biochemistry, Endocrinology +17

Probing the α‐Helical Structural Stability of Stapled p53 Peptides: Molecular Dynamics Simulations and Analysis

Zuojun Guo, Udayan Mohanty, Justin Noehre et al. · Chemical Biology & Drug Design · 2010 · 388 citations

Life Sciences, Biochemistry, Molecular Biology +17

Discovery of 3-[2-(Imidazo[1,2-<i>b</i>]pyridazin-3-yl)ethynyl]-4-methyl-<i>N</i>-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant

Wei‐Sheng Huang, Chester A. Metcalf, Raji Sundaramoorthi et al. · Journal of Medicinal Chemistry · 2010 · 362 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12